CVS Caremark is taking the reigns of Coram Specialty Infusion Services from healthcare group Apria, for $2.1 billion a press release on the company's website reported Wednesday.
"Bringing together CVS Caremark's unique range of specialty pharmacy services with Coram's infusion capabilities will expand our competitive offerings in the specialty arena," Jonathan Roberts, the president of CVS Caremark Pharmacy Services, said in a statement. "Infusion will be a valuable component of our broad specialty pharmacy offering going forward."
Coram anticipates bringing in $1.4 billion in income after the initial year of the transaction concludes following next year's first fiscal quarter. This also involves expenses to integrate the deal, and a deposit.
According to Street Insider, the transaction will not impact CVS Caremark's monetary results for 2014. It will rather increase its altered earnings three to five cents a share the next year, 2015.
"CVS Caremark and Coram share a mutual commitment to provide patients with quality care," John Figueroa, chief executive officer of Coram LLC and Chairman of the Board of Directors for Apria Healthcare Group said in a statement. "Coram has a demonstrated track record of providing access to infusion services delivered by experienced and knowledgeable clinical staff."
Coram offers anti-infective services, TPN and tube feeding, Cardiac and inotropic therapies, Immunoglobulins (IVIg and SCIg), Pre- and post-transplant therapies, alpha-1 therapies, hemophilia services, pain and palliative care services, ambulatory infusion suites, and coram specialty pharmacy Services. This also includes a web of over 85 sites for infusions or the process used to insert liquid into a vein.
Customers may be able to fund the expenses for infusion, and particular medicines via medical coverage or deals at a pharmacy
CVS Caremark strives to offer a full array of options for clients and patients. These include strategies for better managing particular expenditures pharmacies have the press release reported.
